Results 81 to 90 of about 474,213 (268)

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

npj Breast Cancer
In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment.
Rodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, Elia Seguí, Esther Carcelero, Pablo Tolosa, Jesús Soberino, Manuel Alva, Tomás Pascual, Laura Lema, Isabel Garcia-Fructuoso, Maria Angeles Cobos-Fernandez, Maria Rey, Luis Manso, Angela Aguirre, Ainhoa Madariaga, Valeria Sirenko, Cristina González-Deza, Paula Blasco, Astrid Mayhua, Oleguer Castillo, Patricia Galván, Esther Sanfeliu, Guillermo Villacampa, Wesley Buckingham, Mercedes Marín-Aguilera, Laia Paré, Patricia Villagrasa, Charles M. Perou, Julia Maues, Fara Brasó-Maristany, Eva Ciruelos, Aleix Prat   +32 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

Scientific Reports
HER2 overexpression/amplification (HER2+) occurs in approximately 15–20% of breast cancer (BC) and identifies a highly aggressive BC subtype. The cure rate of HER2 + BC has been significantly increased through recent clinical achievements; however, a non-
Lorenzo Castagnoli, Francesco Bonì, Martina Bigliardi, Paolo Toneguzzo, Paola A. Corsetto, Giorgia Galasso, Alma Franceschini, Paolo Cocomazzi, Viola Regondi, Cristian Capuzzoni, Angela M. Rizzo, Francesca Ligorio, Claudio Vernieri, Pierfausto Seneci, Daniela Arosio, Elda Tagliabue, Eloise Mastrangelo, Mario Milani, Serenella M. Pupa   +18 more
doaj   +1 more source

Platelets and platelet-derived extracellular vesicles: their role in lung cancer dissemination and premetastatic niche formation

Frontiers in Immunology
Metastasis, the primary cause of cancer-related mortality, is sustained by complex interactions between tumor cells and host-derived factors. Extracellular vesicles, membrane-bound particles that mediate intercellular communication, have emerged as ...
Camilla Locatelli, Camilla Locatelli, Nicole Ferrario, Orazio Fortunato, Patrizia Ghidotti, Rossella Crescitelli   +5 more
doaj   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Dysbiosis and extraintestinal cancers

Journal of Experimental & Clinical Cancer Research
The gut microbiota plays a crucial role in safeguarding host health and driving the progression of intestinal diseases. Despite recent advances in the remarkable correlation between dysbiosis and extraintestinal cancers, the underlying mechanisms are yet
Ruishan He, Pingqian Qi, Linzhen Shu, Yidan Ding, Peng Zeng, Guosheng Wen, Ying Xiong, Huan Deng   +7 more
doaj   +1 more source

MiRNAs: a call to arms that shapes the plasticity of tumor associated macrophages in breast cancer

Frontiers in Immunology
Breast cancer (BC) remains a leading cause of cancer-related mortality, and a major contribution to tumor progression and resistance to therapies arise from tumor microenvironment (TME).
Valentina Fogazzi, Giulia Cosentino, Michele Sommariva, Michele Sommariva, Angela Galardi, Elisa Dell’Orto, Serenella M. Pupa, Cristian Taccioli, Cristian Taccioli, Marilena V. Iorio   +9 more
doaj   +1 more source